OmniAb, Inc. Warrant 2022- on Omniab Inc OABIW 深 滬
等待開盤 07-31 09:30:00 美东时间
0.0834
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0834
- 總市值 0
- 52周最高 0.28
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.04
- 委 比 76.47%
- 總股本 --
- 歷史最高 1.50
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.04
- 每 手 1
- 風險率 0.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
Austin, Texas, United States, July 27th, 2026, FinanceWire VERAXA Biotech (NASD...
07-28 02:30
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb, Inc. (NASDAQ...
07-27 19:07
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech AG and OmniAb, Inc. announce the advancement of their bispecific ADC (bsADC) program VXA-222, utilizing an "AND-gate" logic to target two solid tumor antigens. Following successful completion of OmniAb's discovery work, the program enters its next phase, combining OmniAb's antibody solutions with VERAXA's ADC linker technology. VERAXA will develop and validate the lead candidate, with exclusive rights to commercialize products inco...
07-27 11:00
OmniAb Names Amechi Nwachuku Chief Operating Officer
The latest update is out from OmniAb ( ($OABI) ). Effective July 13, 2026, Omni...
07-13 20:48
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
VERAXA Biotech AG has made significant progress in its BiTAC® platform for developing conditionally active T cell engagers and antibody-drug conjugates. The company plans to prioritize investments in BiTAC-based therapies, aiming to advance VXA-102 to IND/CTA readiness by early 2028. With four BiTAC programs targeting solid tumors and two bispecific ADCs, VERAXA is leveraging its differentiated technology to attract partnerships, especially follo...
07-06 11:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 147.2% to ...
05-20 20:06
OmniAb forecasts $28M-$33M 2026 revenue as partner milestones lift outlook
Earnings Call Insights: OmniAb, Inc. (OABI) Q1 2026 Management view "OmniAb delivered a very strong start to the year, largely driven by advancement of our partner programs," said President, CEO & Dir...
05-08 11:02
OmniAb Sees FY2026 Sales $25.000M-$30.000M vs $31.996M Est
OmniAb (NASDAQ:OABI) sees FY2026 sales of $25.000 million-$30.000 million vs $31.996 million analyst estimate.
03-05 05:08
